Heidelberg Pharma AG banner

Heidelberg Pharma AG
XETRA:HPHA

Watchlist Manager
Heidelberg Pharma AG Logo
Heidelberg Pharma AG
XETRA:HPHA
Watchlist
Price: 3.04 EUR 0.33%
Market Cap: €142.2m

Wall Street
Price Targets

HPHA Price Targets Summary
Heidelberg Pharma AG

Wall Street analysts forecast HPHA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HPHA is 5.61 EUR with a low forecast of 5.56 EUR and a high forecast of 5.78 EUR.

Lowest
Price Target
5.56 EUR
83% Upside
Average
Price Target
5.61 EUR
85% Upside
Highest
Price Target
5.78 EUR
90% Upside
Heidelberg Pharma AG Competitors:
Price Targets
QLYS
Qualys Inc
39% Upside
UFPT
UFP Technologies Inc
20% Upside
MASI
Masimo Corp
44% Upside
NYXH
Nyxoah SA
151% Upside
VERK
Verkkokauppa.com Oyj
23% Upside

Revenue
Forecast

22% / Year
Past Growth
25% / Year
Estimated Growth
Estimates Accuracy
-30%
Average Miss
22% / Year
Past Growth
25% / Year
Estimated Growth
Estimates Accuracy
-30%
Average Miss

For the last 8 years the compound annual growth rate for Heidelberg Pharma AG's revenue is 22%. The projected CAGR for the next 3 years is 25%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
4%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-35%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-35%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HPHA's stock price target?
Price Target
5.61 EUR

According to Wall Street analysts, the average 1-year price target for HPHA is 5.61 EUR with a low forecast of 5.56 EUR and a high forecast of 5.78 EUR.

What is Heidelberg Pharma AG's Revenue forecast?
Projected CAGR
25%

For the last 8 years the compound annual growth rate for Heidelberg Pharma AG's revenue is 22%. The projected CAGR for the next 3 years is 25%.

Back to Top